Pituitary surgery represents the first-line treatment for most patients with Cushing’s disease (CD). In the case of surgery failure, additional treatment options are required. Pasireotide has shown favourable results in the first-line treatment of patients with CD, who are not candidates for surgery or in the second-line when surgery has failed. The aim of the current study is to compare the effects of surgery and pasireotide treatment in a cohort of patients with CD, and to evaluate the differences in response rate in terms of hormonal and clinical control, and improvement of metabolic complications.
Guarnotta, V., Ciresi, A., Pizzolanti, G., & Giordano, C. (2017). Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease. In Abstract Book SIE 2017 (pp.190-190).
Autori: | Guarnotta, V.; Ciresi, A.; Pizzolanti, G.; Giordano, C. |
Titolo: | Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease |
Settore Scientifico Disciplinare: | Settore MED/13 - Endocrinologia |
Data di creazione: | 2017-01-06 |
Nome del convegno: | 39° Congresso Nazionale della Società italiana di Endocrinologia |
Luogo del convegno: | Roma |
Anno del convegno: | 21-24.06.2017 |
Data di concessione: | 2017-01-06 |
Data di pubblicazione: | 2017 |
Formato: | A stampa |
Numero di pagine: | 1 |
Citazione: | Guarnotta, V., Ciresi, A., Pizzolanti, G., & Giordano, C. (2017). Comparison of clinical and metabolic effects of pasireotide and pituitary surgery in Cushing disease. In Abstract Book SIE 2017 (pp.190-190). |
Tipologia: | 0 - Proceedings (TIPOLOGIA NON ATTIVA) |
Appare nelle tipologie: | 0 - Proceedings (TIPOLOGIA NON ATTIVA) |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
Guarnotta - pasireotide.pdf | abstract | N/A | Open Access Visualizza/Apri |